Loading
companiesCompany
Fusion Pharmaceuticals (AstraZeneca)
Alpha-emitter company acquired by AstraZeneca ($2.4B, 2024); FPI-2265 (225Ac-PSMA-I&T) in phase 3.
Overview
Fusion Pharmaceuticals, based in Hamilton, Ontario, is the alpha-emitter company acquired by AstraZeneca for 2.4 billion dollars in 2024, and its FPI-2265, an actinium-225 PSMA-I&T agent, is in phase 3. Its pipeline also includes FPI-2068, an EGFR by c-MET bispecific radioconjugate, and the company holds actinium-225 supply agreements. OnCo links it to the AlphaBreak trial of FPI-2265 and the AcTION trial of 225Ac-PSMA-617, to targeted alpha therapy, to the actinium-225 PSMA agents record and to the radiopharmaceutical roadmap. Whether actinium PSMA therapy can improve on lutetium PSMA therapy is the question AlphaBreak will answer. Actinium-225 PSMA agents have their own page.
Headquarters
Hamilton, ON, CA
Scorecard
All companies#439of 1244 companies, score 7
- phase 3 +3
- targets +2
- modalities +2
0 approved, 1 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-03-19 | Fusion Pharmaceuticals (AstraZeneca) to AstraZeneca FPI-2265 (actinium-225 PSMA) and the Fusion targeted alpha therapy platform | Acquisition | $2.0bn | up to $2.4bn including a contingent value right | source |
Website
Phase 3Targeted alpha therapy
Alpha-emitting PSMA drugs that produce responses even after Pluvicto fails, held back mainly by isotope supply.
Similar pages
- PairingBeta radioligand → alpha radioligand
Shares Actinium-225 PSMA agents, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- PersonClemens Kratochwil
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
- CompanyTerraPower Isotopes
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- CompanyRayzeBio (BMS)
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
- CompanyITM Isotope Technologies Munich
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- CompanyOrano Med
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
fronts
technologies
drugs
Phase 3Targeted alpha therapy